Stocks
Fate Therapeutics (FATE) EBITDA margin US GAAP (year values) |
|||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | CAGR 5 years ? | |||
| EBITDA margin, % | ? | -902.6% | -399.8% | -386.2% | -320.2% | -250.8% | -3 069% | ||
| Changes by years, y/y, % | +467pp | +503pp | +14pp | +66pp | +69pp | -28.8% | |||
Fate Therapeutics. EBITDA margin, %
Fate Therapeutics. EBITDA margin, changes, pp
Fate Therapeutics (FATE) EBITDA margin US GAAP (quarter values) |
||||||||
| 2023Q1 | 2023Q2 | 2023Q3 | 2023Q4 | 2024Q1 | LTM ? | |||
| EBITDA margin, % | ? | -41.4% | -6 227% | -2 638% | -2 577% | -2 402% | -3 069% | |
| Changes by years, y/y, % | +348pp | -5 795pp | -2 082pp | -2 432pp | -2 361pp | |||
| Changes by quarters, q/q, % | +104pp | -6 186pp | +3 589pp | +61pp | +175pp | |||
